We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+11.18%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$900M
AUM Growth
-$66.1M
Cap. Flow
-$123M
Cap. Flow %
-13.72%
Top 10 Hldgs %
42.92%
Holding
115
New
38
Increased
27
Reduced
28
Closed
14

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$34.5M
2
UTHR icon
United Therapeutics
UTHR
+$23.6M
3
HUM icon
Humana
HUM
+$19.6M
4
SKIN icon
SkinHealth Systems
SKIN
+$14.5M
5
MCRB icon
Seres Therapeutics
MCRB
+$11.1M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$51.8M
2
EXAS
Exact Sciences
EXAS
+$30.2M
3
SNN icon
Smith & Nephew
SNN
+$14.9M
4
SIBN icon
SI-BONE Inc
SIBN
+$10.6M
5
ACLX
Arcellx
ACLX
+$9.41M

Sector Composition

Rank Sector Weight
1 Healthcare 96.82%
2 Consumer Staples 2.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$26.3B
$53.6M 5.96%
242,735
+106,500
+78% +$23.6M
FOCL
2
EDAP TMS S.A.
FOCL
$226M
$50.5M 5.61%
5,474,222
+162,000
+3% +$1.66M
CRL icon
3
Charles River Laboratories
CRL
$10.9B
$44M 4.9%
209,496
+53,400
+34% +$10.6M
SRDX
4
DELISTED
Surmodics
SRDX
$41.9M 4.65%
1,336,838
+444,160
+50% +$10.1M
ORGO icon
5
Organogenesis Holdings
ORGO
$308M
$38.9M 4.33%
11,728,063
+1,875,000
+19% +$5.54M
IRMD icon
6
iRadimed
IRMD
$1.21B
$36.9M 4.11%
773,694
– –
TEVA icon
7
Teva Pharmaceuticals
TEVA
$35.9B
$32M 3.56%
+4,250,000
New +$34.5M
ACLX
8
DELISTED
Arcellx
ACLX
$31.7M 3.52%
1,001,999
-246,148
-20% -$9.41M
PCVX icon
9
Vaxcyte
PCVX
$7.89B
$28.5M 3.17%
571,250
+191,000
+50% +$9.05M
HUM icon
10
Humana
HUM
$46.7B
$28.1M 3.12%
62,750
+39,000
+164% +$19.6M
CVS icon
11
CVS Health
CVS
$137B
$24.5M 2.73%
355,054
+111,500
+46% +$7.93M
CELC icon
12
Celcuity
CELC
$4.03B
$21.1M 2.35%
1,923,283
+235,350
+14% +$2.45M
SKIN icon
13
SkinHealth Systems
SKIN
$94.9M
$20.8M 2.31%
2,481,789
+1,391,837
+128% +$14.5M
RIGL icon
14
Rigel Pharmaceuticals
RIGL
$680M
$18.3M 2.03%
1,417,802
+137,500
+11% +$1.86M
SIBN icon
15
SI-BONE Inc
SIBN
$737M
$16.9M 1.88%
626,144
-434,839
-41% -$10.6M
AXGN icon
16
Axogen
AXGN
$2.1B
$16.3M 1.82%
1,789,998
+10,000
+0.6% +$93.2K
SNN icon
17
Smith & Nephew
SNN
$12.9B
$15.8M 1.75%
489,268
-480,932
-50% -$14.9M
SGEN
18
DELISTED
Seagen Inc. Common Stock
SGEN
$13.7M 1.52%
71,000
– –
BCAB icon
19
BioAtla
BCAB
$5.59M
$13M 1.44%
86,424
– –
KRYS icon
20
Krystal Biotech
KRYS
$9.88B
$12.9M 1.44%
110,192
+25,013
+29% +$2.55M
INBX
21
DELISTED
Inhibrx, Inc. Common Stock
INBX
$12.3M 1.37%
473,183
+35,181
+8% +$822K
EPIX
22
DELISTED
ESSA Pharma
EPIX
$11.3M 1.26%
4,202,094
+56,977
+1% +$167K
NPCE icon
23
Neuropace
NPCE
$505M
$11.1M 1.23%
2,466,214
+37,500
+2% +$170K
TGTX icon
24
TG Therapeutics
TGTX
$8.58B
$10.8M 1.2%
435,500
-314,800
-42% -$8.13M
JSPR icon
25
Jasper Therapeutics
JSPR
$22.9M
$10.7M 1.18%
777,598
+32,100
+4% +$477K
1
2 3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Soleus Capital Management held 115 positions worth $900M, down 6.9% from $966M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Soleus Capital Management withdrew a net $123M in Q2 2023, closing 14 positions and reducing 28 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $51.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 81% a quarter earlier, followed by Consumer Staples.

Against the trend, Soleus Capital Management opened a new position in Teva Pharmaceuticals worth $32M.

  • Soleus Capital Management's largest Q2 2023 buy was Teva Pharmaceuticals: 4,250,000 shares worth $32M.
  • Soleus Capital Management added most to United Therapeutics in Q2 2023, an estimated $23.6M increase.
  • Soleus Capital Management's biggest Q2 2023 reduction was Exact Sciences, cutting an estimated $30.2M.
  • Soleus Capital Management fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $51.8M.
  • Soleus Capital Management's ten largest holdings make up 43% of its $900M portfolio in Q2 2023.
  • Soleus Capital Management opened 38 new positions and closed 14 in Q2 2023.
  • Soleus Capital Management's portfolio value fell 6.9% quarter-over-quarter to $900M.

Based on Soleus Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.